Feng Yilin, Venkateswaran Nandini, Steele Amanda, Rosenberg Eric D, Gupta Preeya K
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Triangle Eye Consultants, Raleigh, NC, USA.
Clin Ophthalmol. 2024 Oct 10;18:2873-2878. doi: 10.2147/OPTH.S469300. eCollection 2024.
To evaluate the impact of TearCare (TC) treatment on clinical, quality of life, and functional visual outcome metrics in patients with dry eye disease (DED) and meibomian gland disease (MGD).
This is a prospective, single-center clinical trial. Adults with MGD and a DED diagnosis and tear break-up time (TBUT) <10 seconds were included. All subjects had at least 20/40 vision and no surgery or new treatment for DED within 60 days prior to enrollment. All patients had one baseline visit prior to undergoing TC and one follow-up visit 1 month after TC. At each visit, the meibomian gland secretion score (MGSS), TBUT, and corneal fluorescein staining (KFL) were assessed. DED symptoms were evaluated using the Ocular Surface Disease Index (OSDI) questionnaire, Visual Function Questionnaire 25 (VFQ-25), and the Fatigue Severity Scale. Reading speed was determined through the International Reading Speed Texts (IReST), Minnesota Low Vision Reading Test (MNREAD), and Wilkins Rate of Reading Test (WRRT).
Thirty-two subjects were included. The average age was 55.9 years. Sixteen (52%) participants had a clinically significant improvement in reading speed after treatment with TC, defined as >10 words per minute increase in their IReST score. Improvement on the IReST and the MNREAD reached statistical significance (p = 0.012 and p = 0.028, respectively). OSDI scores significantly decreased and VFQ-25 scores significantly increased after TC treatment (p < 0.001). All of the clinical exam parameters showed statistically significant improvements after treatment (p < 0.001).
TC is an effective treatment both clinically and with respect to visual function. Patients who had TC exhibited improvements in quality of life and improved reading speed after a single treatment. This treatment should be frequently considered and utilized to reduce the disease burden of DED related to MGD.
评估泪道护理（TC）治疗对干眼症（DED）和睑板腺疾病（MGD）患者的临床、生活质量及功能性视觉结果指标的影响。
这是一项前瞻性单中心临床试验。纳入患有MGD且诊断为DED、泪膜破裂时间（TBUT）<10秒的成年人。所有受试者视力至少为20/40，且在入组前60天内未接受过DED的手术或新治疗。所有患者在接受TC治疗前进行一次基线访视，治疗后1个月进行一次随访。每次访视时，评估睑板腺分泌评分（MGSS）、TBUT和角膜荧光素染色（KFL）。使用眼表疾病指数（OSDI）问卷、视觉功能问卷25（VFQ - 25）和疲劳严重程度量表评估DED症状。通过国际阅读速度文本（IReST）、明尼苏达低视力阅读测试（MNREAD）和威尔金斯阅读速度测试（WRRT）确定阅读速度。
纳入32名受试者。平均年龄为55.9岁。16名（52%）参与者在接受TC治疗后阅读速度有临床显著改善，定义为IReST评分每分钟增加>10个单词。IReST和MNREAD的改善达到统计学意义（分别为p = 0.012和p = 0.028）。TC治疗后OSDI评分显著降低，VFQ - 25评分显著升高（p < 0.001）。所有临床检查参数在治疗后均有统计学显著改善（p < 0.001）。
TC在临床和视觉功能方面都是一种有效的治疗方法。接受TC治疗的患者在单次治疗后生活质量得到改善，阅读速度提高。应经常考虑并采用这种治疗方法来减轻与MGD相关的DED疾病负担。
